drugset / Trial / NCT00354120

Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant

NCT00354120

Phase 2/3 Completed 121 enrolled Italian Group for Bone Marrow Transplantation
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare Reduced Intensity Conditioning protocols containing either Thymoglobuline or Alemtuzumab in patients undergoing allogeneic transplant from voluntary unrelated donors.

Timeline

Start
2005-03
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Alemtuzumab Monoclonal antibody
Comparator Globulina antilinfocitaria Unknown